Cargando…
HLA-B*5701 testing to predict abacavir hypersensitivity
Abacavir is a nucleoside reverse transcriptase inhibitor used for combination antiretroviral therapy for treating human immunodeficiency virus (HIV) infection. An adverse effect from abacavir is a treatment-limiting hypersensitivity reaction, which can be severe and potentially life-threatening. Aba...
Autores principales: | Ma, Joseph D., Lee, Kelly C., Kuo, Grace M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000684/ https://www.ncbi.nlm.nih.gov/pubmed/21151380 http://dx.doi.org/10.1371/currents.RRN1203 |
Ejemplares similares
-
Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients
por: Baniasadi, Shadi, et al.
Publicado: (2016) -
Prevalence of the HLA-B*5701 Allele and Abacavir Hypersensitivity in Saudi HIV Patients: A Multicenter Study
por: Alsaeed, Ali, et al.
Publicado: (2023) -
Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus
por: Nguyen, Christine M., et al.
Publicado: (2011) -
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure
por: Stainsby, Chris M., et al.
Publicado: (2018) -
Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
por: Nguyen, Christine M., et al.
Publicado: (2011)